1Tilburt JC and Kaptchuk TJ (2008) Herbal medicine research and global health: an ethical analysis. Bull World Health Organ 86: 594-599.
2World Health Organization, Programme on Traditional Medicine (2000) General guidelines for methodologies on research and evaluation of traditional medicine, World Health Organization, Geneva.
3Gunther S, Patterson RE, Kristal AR, Stratton KL, White E (2004) Demographic and health-related correlates of herbal and specialty supplement use. J Am Diet Assoc 104: 27-34.
4Mehta DH, Gardiner PM, Phillips RS, McCarthy EP (2008) Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. J Altern Complement Med 14: 1263-1269.
5Riley TH (2010) Dietary supplements: primer and FDA oversight, Nova Science, New York.
6Schmitz SM, Lopez HL, Mackay D (2014) Nutravigilance: principles and practices to enhance adverse event reporting in the dietary supplement and natural products industry. Int J Food Sci Nutr 65: 129-134.
7Chen XW, Sneed KB, Pan SY, Cao C, Kanwar JR, et al. (2012) Herb-drug interactions and mechanistic and clinical considerations. Curr Drug Metab 13: 640-651.
8de Lima Toccafondo Vieira M, Huang SM (2012) Botanical-drug interactions: a scientific perspective. Planta Med 78: 1400-1415.
9He SM, Yang AK, Li XT, Du YM, Zhou SF (2010) Effects of herbal products on the metabolism and transport of anticancer agents. Expert Opin Drug Metab Toxicol 6: 1195-1213.
10Hu Z, Yang X, Ho PC, Chan SY, Heng PW, et al. (2005) Herb-drug interactions: a literature review. Drugs 65: 1239-1282.
11Izzo AA, Ernst E (2009) Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 69: 1777-1798.
12Tarirai C, Viljoen AM, Hamman JH (2010) Herb-drug pharmacokinetic interactions reviewed. Expert Opin Drug Metab Toxicol 6: 1515-1538.
13Yang AK, He SM, Liu L, Liu JP, Wei MQ, et al. (2010) Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem17: 1635-1678.
14Zhou SF, Zhou ZW, Li CG, Chen X, Yu X, et al. (2007) Identification of drugs that interact with herbs in drug development. Drug Discov Today 12: 664-673.
15Lee SS, Zhang B, He ML, Chang VS, Kung HF (2007) Screening of active ingredients of herbal medicine for interaction with CYP450 3A4. Phytother Res 21: 1096-1099.
16Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW (2003) Interactions of herbs with cytochrome P450. Drug Metab Rev 35: 35-98.
17Zhou S, Lim LY, Chowbay B (2004) Herbal modulation of P-glycoprotein. Drug Metab Rev 36: 57-104.
18Zhou SF (2008) Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38: 802-832.
19Brantley SJ, Graf TN, Oberlies NH, Paine MF (2013) A systematic approach to evaluate herb-drug interaction mechanisms: investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors. Drug Metab Dispos 41: 1662-1670.
20Tsai HH, Lin HW, Lu YH, Chen YL, Mahady GB (2013) A review of potential harmful interactions between anticoagulant/antiplatelet agents and Chinese herbal medicines. PLoS One 8: e64255.
21Berginc K , Kristl A (2013) The mechanisms responsible for garlic - drug interactions and their in vivo relevance. Curr Drug Metab 14: 90-101.
22Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, et al. (2001) An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 4: 176-184.
23Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J (2002) The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 34: 234-238.
24Kim AE, Dintaman JM, Waddell DS, Silverman JA (1998) Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 286: 1439-1445.
25Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, et al. (2000) The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 28: 1058-1062.
26Makino T, Wakushima H, Okamoto T, Okukubo Y, Saito K, et al. (2002) Effects of Kangen-karyu on coagulation system and platelet aggregation in mice. Biol Pharm Bull 25: 523-525.
27Samuels N (2005) Herbal remedies and anticoagulant therapy. Thromb Haemost 93: 3-7.
28Makino T, Wakushima H, Okamoto T, Okukubo Y, Deguchi Y, et al. (2002) Pharmacokinetic interactions between warfarin and kangen-karyu, a Chinese traditional herbal medicine, and their synergistic action. J Ethnopharmacol 82: 35-40.
29Qiu F, Zhang R, Sun J, Jiye A, Hao H, et al. (2008) Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos 36: 1308-1314.
30Shinozuka K, Umegaki K, Kubota Y, Tanaka N, Mizuno H, et al. (2002) Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci 70: 2783-2792.
31von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, et al. (2004) Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 56: 1039-1044.
32Gertz HJ, Kiefer M (2004) Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr Pharm Des 10: 261-264.
33Mahady GB (2002) Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature. J Cardiovasc Nurs 16: 21-32.
34Izzo AA, Di Carlo G, Borrelli F, Ernst E (2005) Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 98: 1-14.
35Chan K (2003) Some aspects of toxic contaminants in herbal medicines. Chemosphere 52: 1361-1371.
36Fugh-Berman A (2000) Herb-drug interactions. Lancet 355: 134-138.
37Castellone DD, Van Cott EM (2010) Laboratory monitoring of new anticoagulants. Am J Hematol 85: 185-187.
38Ernst E, Pittler MH (2002) Herbal medicine. Med Clin North Am 86: 149-161.
39Yang XX, Hu ZP, Duan W, Zhu YZ, Zhou SF (2006) Drug-herb interactions: eliminating toxicity with hard drug design. Curr Pharm Des 12: 4649-4664.